Wearable device could treat chronic migraine
Theranica, a a digital therapeutics company that develops products for migraines and other pain conditions has developed Nerivio® to treat acute chronic migraines in people aged 18 years and over.
Controlled by a smartphone app, the device uses Remote Electrical Neuromodulation (REN) to activate a mechanism in the brain that can treat pain and accompanying migraine symptoms. Nerivio is one of TIME magazine's best inventions of 2019.
According to the Migraine Research Foundation, more than 4 million adults in the US experience chronic migraines , with at least 15 migraine days per month. While most medication for migraines has limited monthly usage before it stops being effective, Nerivio has been shown in clinical trials to be effective without risks of medication overuse. As a result it's received clearance from the US Food and Drug Administration (FDA) for this expanded treatment indication.
Prof. Stephen Silberstein MD, the director of the Headache Center at the Jefferson University Hospital in Philadelphia and a member of Theranica’s Medical Advisory Board explains: “The updated Nerivio indication is an important development for patients with chronic migraine”.
"When chronic patients find an effective treatment, they must limit its use every month to avoid loss of effectiveness and a risk of medication overuse headache. Availability of an additional treatment option such as Nerivio provides an important additional tool to address this patient population.”
He added: “With over one thousand treatments by 130 chronic migraine patients across two open-label studies with Nerivio, the data is clinically relevant.”
Nancy Harris Bonk, a migraine patient advocate and Chief Operating Officer of Chronic Migraine Awareness, Inc, commented: “It is so important for people living with chronic migraine to now have access to this effective non-pharmacological therapy."
“With migraine attacks occurring so frequently, we, people with chronic migraine, need to be mindful of overusing medications, and identify the right individual balance of therapies that allows us to carry on with our daily routines.”
Nerivio can currently be obtained by prescription and is delivered directly to patients' homes. Each Nerivio is good for 12 treatments, after which it can be recycled, and the prescription refilled with a new dispensed device.
Bachem turns 50 - a timeline
Bachem, a supplier to pharmaceutical and biotechnology companies worldwide, is celebrating its 50th anniversary this month. We take a look at the Swiss company's history.
1971 - beginnings
Bachem is founded by entrepreneur Peter Grogg in Liestal, a small town near Basel in Switzerland. Grogg started the firm with just two employees, and with a focus on peptide synthesis - peptides are composed of amino acids that have a variety of functions treating health conditions such as cancer and diabetes.
1977 - 1981 - early growth
Bachem moves its headquarters to the Swiss town of Bubendorf, with eight employees. In 1978 the company produces peptides for use in medicines for the first time. In 1981 production capacity triples and the workforce grows to 150.
1987 - 1996 - worldwide expansion
The company expands into the US with Bachem Bioscience, Inc. in Philadelphia. To strengthen its presence in Europe, Bachem opens sales and marketing centres in Germany in 1988.
Further sales centres open in France in 1993. By 1995 the company employs 190 people. In 1996 it acquires the second largest manufacturer of peptides in the world and forms Bachem California with a site in Torrance.
1998 - 2003 - Bachem goes public
Bachem company goes public and lists shares on the Swiss Stock Exchange. Further acquisitions include Peninsula Laboratories, Inc, based in California, and Sochinaz SA, a Swiss-based manufacturer of active pharmaceutical ingredients. By 2001, the company has 500 employees and sales reach 141 million CHF.
In 2003 the organisation is given a new legal holding structure to support its continued growth, which remains in place to this day.
2007 - 2013 - acquisitions
Bachem acquires a brand by Merck Biosciences for ready-to-use clinical trial materials and related services.
In 2013, together with GlyTech, Inc. Bachem announces the development of a new amino acid that can help to treat multiple sclerosis, with a world market of more than $4 billion.
In 2015 it acquires the American Peptide Company (APC), which becomes integrated into Bachem Americas.
2016 - 2019 - a global leader
In 2016 the group opens a new building dedicated to R&D projects and small series production in Bubendorf. With a total of 1,022 employees, the workforce exceeds the 1,000 mark for the first time in the company’s history. Sales are over the 200 million mark for the first time at 236.5 million CHF.
Bachem expands into Asia with the establishment of a new company in Tokyo called Bachem Japan K.K.
By 2019 Bachem has a growing oligonucleotide portfolio - these are DNA molecules used in genetic testing, research, and forensics. It is hoped this will become a significant product range in the future.
2020 - COVID-19
Despite the COVID-19 pandemic, Bachem secures its supply of active ingredients, and even increases it in critical areas. Sales exceed the 400 million Swiss franc mark for the first time, and 272 new employees are hired.
2021 - a milestone anniversary
Bachem celebrates its 50th anniversary and position as a global leader in the manufacture of peptides. While it remains headquartered in Bubendorf, the company employs 1,500 people at six locations worldwide. In the next five years there are plans to continue expanding.
Commemorating the company's anniversary, Kuno Sommer, Chairman of the Board of Directors, said: "Bachem's exceptional success story from a small laboratory to a global market leader is closely linked to Peter Grogg's values, and has been shaped by innovation, consistent quality and cost awareness, as well as by entrepreneurial vision."